Photo taken from Paolo Tarantino/X
Mar 24, 2024, 08:23
Paolo Tarantino: Adding palbociclib to fulvestrant did not improve PFS in the PACE randomized phase 2 trial
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Out in JCO, the PACE randomized phase 2 trial by Erica Mayer, Sara Tolaney et al. Among pts with HR+ MBC and prior progression on CDK4/6i (90% palbo), adding palbo to fulvestrant did not improve PFS (4.6 vs 4.8 mo). Interesting signal with fulv/palbo/avelumab.”
Source: Paolo Tarantino/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 1, 2024, 19:12
Nov 1, 2024, 17:46
Nov 1, 2024, 17:41
Nov 1, 2024, 17:27